IDEXX Laboratories (IDXX) — AI Analysis & Mentions

IDEXX is trading above $550 with an anticipated 13.2% year-over-year earnings growth for the current fiscal year. Six analysts raised fiscal 2026 estimates, taking consensus EPS to $14.81, and the average target price is $747.00. That combination of growth and analyst support makes it one of the more interesting quality-growth names in the feed.

IDXX is trading near record levels because its companion animal diagnostics segment is growing at double-digit rates and the company has solid profitability. The article notes about $4.0 billion in fiscal 2024 revenue, with diagnostics making up the majority and growing 10%. A recurring revenue model built on analyzers and consumables is valuable because it can create a steadier stream of cash over time.

Expected to show robust earnings growth, IDEXX Laboratories demonstrates strong recurring revenue streams. Innovations in veterinary diagnostics also suggest continued relevance and resilience in its market segment.

IDEXX Laboratories has significantly outperformed the market with a remarkable 26.23% average annual return over the past decade. This highlights the company's strong position in the life sciences sector and its potential for continued growth.

IDEXX Laboratories has provided a compelling average return of 12.2% annually over the past 20 years, its market cap stands at $53.12 billion. The company’s exceptional positioning in veterinary diagnostics suggests it will likely continue to benefit from increasing pet ownership and related health services.